Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 268 clinical trials
ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)

Pharmacogenomics (PG) offers the opportunity to individualize treatment according to patient genetic variations which influence activity of enzyme metabolizing or acting in the pathway of prescribed chemotherapy drugs. This add-on research aims to prospectively investigate variations in several candidate genes related to all types of chemotherapeutic drugs and TBI used …

lymphoid leukemia
remission
busulfan
cancer
chemotherapy drug
  • 13 views
  • 23 Jan, 2021
  • 8 locations
Safety and Effectiveness of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML) a Cancer of the Blood

Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or is not …

induction chemotherapy
cytarabine
hematologic malignancy
flt3 internal tandem duplication
remission
  • 39 views
  • 15 Apr, 2021
  • 39 locations
Haplo vs. URD in AML

This study compares haplo-identical family donor stem cell transplantation (haplo SCT) to matched unrelated donor transplantation (URD SCT) in adult patients with acute myeloid leukemia (AML) with the hypothesis that haplo SCT is as good as URD SCT. Background A haplo-identical family donor is a relative sharing 50% of the …

cyclophosphamide
hla-a
cell transplantation
busulfan
mycophenolate mofetil
  • 4 views
  • 23 Jan, 2021
  • 14 locations
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.

thalassemia
melphalan
hydroxyurea
hemoglobin s
transplant conditioning
  • 142 views
  • 25 Jan, 2021
  • 20 locations
Fludarabine Based RIC for Bone Marrow Failure Syndromes

This is a pilot study to determine whether fludarabine-based reduced intensity conditioning (RIC) regimens facilitate successful donor engraftment of patients with acquired aplastic anemia (AA

  • 0 views
  • 24 Jan, 2021
  • 1 location
Orally Fludarabine Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL)

The primary objective of this study is to evaluate the efficacy of Fludarabine, Adriamycin and Dexamethasone (FAD) as first line therapy in patients with Peripheral T-cell lymphomas (PTCL

anaplastic large cell lymphoma
large cell lymphoma
neutrophil count
dexamethasone
absolute neutrophil count
  • 19 views
  • 07 Nov, 2020
  • 1 location
Umbilical Cord Blood Transplant Cyclophosphamide Fludarabine and Total-Body Irradiation in Treating Patients With Hematologic Disease

This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with

cyclophosphamide
autograft
acute biphenotypic leukemia
transplant conditioning
mantle cell lymphoma
  • 125 views
  • 11 Apr, 2021
  • 3 locations
Ibrutinib Fludarabine Phosphate Cyclophosphamide and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia

This phase II trial studies how well ibrutinib, fludarabine phosphate, cyclophosphamide, and obinutuzumab work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the

lymphoid leukemia
obinutuzumab
lymphoma
cyclophosphamide
monoclonal protein
  • 0 views
  • 25 Jan, 2021
  • 1 location
Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation

transplants). The hypothesis is that thiotepa at a dose of 10mg/kg, in combination with melphalan (100mg/m2) and fludarabine (160mg/m2) as a reduced intensity conditioning regimen for alternative

melphalan
chronic myeloid leukemia
myelodysplasia
myelodysplastic syndromes
hematologic malignancy
  • 12 views
  • 16 May, 2021
  • 1 location
Targeted Busulfan Fludarabine Etoposide Conditioning Regimen for HSCT in Childhood and Adolescent ALL.

To evaluate the outcome of hematopoietic stem cell transplantation using targeted busulfan, fludarabine, etoposide conditioning regimen in childhood and adolescent ALL.

ejection fraction
etoposide
busulfan
fludarabine
transplant conditioning
  • 8 views
  • 07 Apr, 2021
  • 1 location